Retrospective Study
Copyright ©The Author(s) 2020.
World J Gastroenterol. Aug 14, 2020; 26(30): 4465-4478
Published online Aug 14, 2020. doi: 10.3748/wjg.v26.i30.4465
Figure 3
Figure 3 Lenvatinib-related adverse events in patients with hepatocellular carcinoma. The brown bar represents grade 3-4 adverse events; the blue bar represents all-grade adverse events.